Practices are capitalizing on GLP-1 patient demand for non-surgical body tightening and skin quality treatments following significant weight loss.
Blackhawk Plastic Surgery and other medspa operators are reporting a surge in body-contouring and skin-quality treatments among patients undergoing GLP-1 receptor agonist therapy (semaglutide, tirzepatide). The phenomenon reflects a predictable clinical pathway: rapid weight loss via GLP-1 creates loose skin, reduced skin elasticity, and patient demand for non-surgical tightening and texture improvement.
Treatments capturing this demand include RF microneedling (Morpheus8, XERF), monopolar RF, laser resurfacing, and injectables targeting skin quality (Profhilo, Radiesse, Juvéderm). The GLP-1 boom is creating a new patient cohort with both the motivation and disposable income to pursue aesthetic refinement—a tailwind for high-margin medspa services.
GLP-1 weight loss is creating a new medspa patient cohort seeking body contouring and skin-quality treatments.
For practices, this represents an opportunity to expand beyond traditional injectables and develop integrated body-contouring and skin-quality protocols. Marketing to GLP-1 patients and establishing referral relationships with weight-loss clinics or primary-care providers prescribing these agents could become a material revenue driver.
Source: original report ↗
Free alerts Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo Join the owners who run ahead of the industry. Cancel anytime, one click.
